Early Detection Research Network

Pullin, Nancy

Contact Information

Email: mailto:pullinn@uthscsa.edu
Fax:
1665
None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

None Available.

Closed Protocols

No closed protocols.

Publications

Publication Name PubMed ID Journal
A case control study of sarcosine as an early prostate cancer detection biomarker. 26429735 BMC Urol
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. 27431498 Prostate Cancer Prostatic Dis.
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. 23232570 Adv Anat Pathol
A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation. 25684153 J Clin Epidemiol
Active surveillance for prostate cancer. 21119090 JAMA
Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing. 25636657 J. Urol.
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. 24807866 Lancet Oncol.
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. 21350221 J. Natl. Cancer Inst.
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. 22846433 J Proteomics
Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. 12394768 J. Urol.
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. 16622122 J. Natl. Cancer Inst.
Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. 16406987 J. Urol.
Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. 19528667 Carcinogenesis
Association of polymorphisms in TGFB1 and prostate cancer prognosis. 18082198 J. Urol.
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. 17908993 Clin. Cancer Res.
Biomarker-based methods for determining noncompliance in a prevention trial. 12505245 Control Clin Trials
Biomarkers for prostate cancer detection. 17936845 J. Urol.
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. 20142396 Am. J. Epidemiol.
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. 20739049 Urology
Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. 18361412 Prostate
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. 18544568 Carcinogenesis
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. 16618725 Cancer Res.
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. 26332453 Prostate
Erectile dysfunction and subsequent cardiovascular disease. 16414947 JAMA
Erectile dysfunction and subsequent cardiovascular disease. 16414947 JAMA
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. 17169636 Urology
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. 17437804 J. Urol.
Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. 25090603 JAMA
Future directions in the prevention of prostate cancer. 24281061 Nat Rev Clin Oncol
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. 23476788 Prostate Cancer
Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities. 28413904 Am J Mens Health
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. 27635949 Am. J. Surg. Pathol.
Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. 25989018 J Biomed Inform
Integrating the predictiveness of a marker with its performance as a classifier. 17982157 Am. J. Epidemiol.
Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. 25686543 J. Urol.
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? 24747090 J. Urol.
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men. 17445654 Urology
Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity? 22822113 Cancer Epidemiol. Biomarkers Prev.
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. 25065737 Prostate
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. 15998892 JAMA
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. 25819722 Eur. Urol.
Predicting prostate cancer risk through incorporation of prostate cancer gene 3. 18707724 J. Urol.
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. 17634486 J. Clin. Oncol.
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. 15163773 N. Engl. J. Med.
Processing of voided urine for prostate cancer RNA biomarker analysis. 26306723 Prostate
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. 21074193 J. Urol.
Prostate cancer detection strategies. 16630521 Curr Urol Rep
Prostate cancer detection: a view of the future. 21130561 Eur. Urol.
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. 24862395 Urology
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. 17991549 Urology
Prostate-specific antigen in the early detection of prostate cancer. 17576986 CMAJ
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. 17405989 J. Natl. Cancer Inst.
Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. 15329895 Cancer
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. 18030357 Neoplasia
Relationship of body mass index and prostate specific antigen in a population-based study. 15082010 Urol. Oncol.
Rethinking screening for breast cancer and prostate cancer. 19843904 JAMA
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. 19683737 J. Urol.
Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. 26979652 J. Urol.
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. 19475640 Prostate
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. 19505920 Cancer Epidemiol. Biomarkers Prev.
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. 20086112 Cancer Epidemiol. Biomarkers Prev.
Temporal changes in the clinical approach to diagnosing prostate cancer. 23271768 J. Natl. Cancer Inst. Monographs
The association of body mass index and prostate-specific antigen in a population-based study. 15668913 Cancer
The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. 24296854 Cancer Epidemiol. Biomarkers Prev.
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. 23313212 J. Urol.
The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. 25636656 J. Urol.
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. 27810448 J. Urol.
Total prostate specific antigen stability confirmed after long-term storage of serum at -80C. 18550121 J. Urol.
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. 23515404 Clin. Cancer Res.
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. 19008263 Mol. Cell Proteomics
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. 19836788 J. Urol.
Validation of genome-wide prostate cancer associations in men of African descent. 21071540 Cancer Epidemiol. Biomarkers Prev.
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. 18483391 Clin. Cancer Res.
What do the screening trials really tell us and where do we go from here? 24725484 Urol. Clin. North Am.
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. 19286205 J. Urol.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.